-transparent.png){kind=logo}
Strontium-89 chloride is a radiopharmaceutical that localizes to actively forming new bone, such as metastatic bone lesions from prostate and breast cancer. It provides effective systemic endo-osseous local radiation therapy to these painful lesions. Strontium-89 will soon be available to physicians in the United States for use in the palliative management of metastatic bone pain.
Related Publications
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
January 1997,
Tumori,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
March 1989,
Radiographics : a review publication of the Radiological Society of North America, Inc,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
May 1997,
Southern medical journal,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
April 1996,
Oncology nursing forum,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
November 2022,
Journal of bone and mineral metabolism,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
January 1995,
Cancer surveys,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
June 2003,
Ortopedia, traumatologia, rehabilitacja,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
April 1985,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
January 2006,
Urologia internationalis,
D V Hansen, and
E R Holmes, and
G Catton, and
D A Thorne, and
D H Chadwick, and
D A Schmutz
May 1995,
Harefuah,
